ASCO GU 2024

Is "more" always better?

Combination vs. monotherapy - a great new option for…

Cabo + IO: Interesting but not practice changing?!

Further testing before olaparib combination

BRCAaway - PARP combination study

Stockholm3 validated in multiethnic cohort

Combination NHT + PARP makes sense

What about the clinical benefit?

Quality of life under intensive therapy

Insights and news for mCRPC

Therapy Intensification Still Neglected in mHSPC

Combination of cabozantinib & checkpoint inhibitor

Cognitive function in ART treatment

Relugolix combined with androgen signaling in real word…

Dose de-escalation in different ways

Localized PCa - news for radiotherapy and biochemical…

Gleason 3+3 - cancer or not?

Evaluating the recombination-repair mutations in…

Long-term dose escalation - Therapy in high-risk…

Higher radiation is effective in high-risk PCA

Salvage radiation with anti-androgen superior to…

Still a difficult time for androgenic inhibitors in…

Olaparib + Arbiraterone better compared to either alone

First positive study of IO therapy in mCRPC

BRCAAway - PARP hämmare, abiraterone eller i…

SEPTA calismasi: Stockholm3 un multietnik hasta…

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi) Orta…

Kombination av cabozantinib och immunterapi

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO…

Une période encore difficile pour les inhibiteurs…

Kognitiv påverkan av abirateron och enzalutamid?

Post-RP salvage radyoterapi hormonoterapi ile konbine…

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

New standard of care, but still open questions!

Advances in (neo)-adjuvant treatment in urothelial…

ADC + ICI: new data for platinum-refractory bladder…

Adjuvant therapy in urothelial carcinoma : is the…

ASCO GU24 - Highlights in Bladder cancer

Highlights in bladder cancer at ASCO GU24

Another success for an ICI?

Should we start forgetting the Galsky Criteria in…

MIBC: adjuvant PD1 - all set?!

Update on EV-302

Biomarker update

EV + Pembro new first-line standard in localized…

HER2 and bladder cancer

Adjuvant Nivolumab Shows Promise in Boosting Long-Term…

Perioperative adjuvant therapy in urothelial cancer

Pembrolizumab adjuvant in bladder cancer

EV as standard in 3rd line mUC

Encore un succès pour une ICI ?

Tratamiento adyuvante en cancer urotelial: ¿está…

Novedades sobre EV-302

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Terapia adyuvante perioperatoria en el cáncer de vejiga

Adjuvant therapy in kidney cancer: Is immunotherapy the…

Subcutaneous vs. intravenous application: ready for…

Trial updates at ASCO GU24: Are the follow-up data…

Cabozantinib Plus Atezolizumab in Adrenocortical…

Practice changing adjuvant therapy?!

Perioperative treatment in renal cell carcinoma - did…

Durable effects of Ipi-Nivo

Long-term follow-up of first-line trials

Overall survival benefit - Pembro after surgery

Tumorburden and outcome

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark…

Long-term outcome

Subcutaneous Nivolumab Matches IV Formulation in Clear…

Better QoL with Belzutifan

Highlights in kidney cancer at ASCO GU24

Belzutifan: Updates on QoL

Long-Term Data on NIVO+IPI in aRCC

Tratamiento perioperatorio en cancer renal: ¿Hemos…